Giles Richard Platford net worth and biography

Giles Platford Biography and Net Worth

President, International Business Unit of Takeda Pharmaceutical

Giles Platford is the president of the International Business Unit (IBU) where he directly oversees all markets outside of the U.S., with the goal of better positioning the company for long-term growth and maximizing the patient impact of Takeda’s current and future portfolio across diverse international markets.

Giles joined Takeda in 2009 as general manager of Brazil and later took on the role of area head for Middle East, Turkey & Africa. He then joined the Takeda Executive Team in 2014 as president of Emerging Markets. In 2017, he became president of Europe & Canada, where he also represented Takeda as a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). In 2022 he became president of the Plasma-Derived Therapies Business Unit, where he also represented the company as chair of the global executive board for the Plasma Protein Therapeutics Association (PPTA).

Giles also serves as a board member of the Healthcare Businesswomen’s Association.

Prior to joining Takeda, Giles spent eight years in Asia Pacific, where he held a number of roles of increasing responsibility in Business Development, Commercial and General Management.

Giles holds a Bachelor of Arts degree in business and marketing management from Oxford Brookes University, UK, and is currently based in Tokyo, Japan.

What is Giles Richard Platford's net worth?: The estimated net worth of Giles Richard Platford is at least $5.50 million as of August 10th, 2026. Mr. Platford owns 315,838 shares of Takeda Pharmaceutical stock worth more than $5,501,898 as of August 13th. This net worth evaluation does not reflect any other assets that Mr. Platford may own. Learn More about Giles Richard Platford's net worth.
How do I contact Giles Richard Platford?: The corporate mailing address for Mr. Platford and other Takeda Pharmaceutical executives is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. Takeda Pharmaceutical can also be reached via phone at (166) 204-2111 and via email at [email protected]. Learn More on Giles Richard Platford's contact information.
Has Giles Richard Platford been buying or selling shares of Takeda Pharmaceutical?: During the last quarter, Giles Richard Platford has sold $531,519.30 of Takeda Pharmaceutical stock. Most recently, Giles Richard Platford sold 31,083 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a transaction totalling $531,519.30. Following the completion of the sale, the insider now directly owns 315,838 shares of the company's stock, valued at $5,400,829.80. Learn More on Giles Richard Platford's trading history.
Are insiders buying or selling shares of Takeda Pharmaceutical?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 430,094 shares worth more than $7,354,607.40. The most recent insider tranaction occured on August, 10th when insider Ramy Riad Ahmed Ibrahim sold 7,277 shares worth more than $124,436.70. Insiders at Takeda Pharmaceutical own 0.0% of the company. Learn More about insider trades at Takeda Pharmaceutical.
Information on this page was last updated on 8/10/2026.

Giles Richard Platford Insider Trading History at Takeda Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2026	Sell	31,083	$17.10	$531,519.30	315,838

Giles Richard Platford Buying and Selling Activity at Takeda Pharmaceutical

Takeda Pharmaceutical Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Today's Range

Now: $17.42

$17.35

$17.47

50 Day Range

MA: $16.49

$15.41

$17.78

2 Week Range

Now: $17.42

$12.99

$18.90

Volume

2,004,364 shs

Average Volume

4,402,927 shs

Market Capitalization

$55.82 billion

P/E Ratio

51.24

Dividend Yield

2.75%

Beta

N/A